On April 13, 2020 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported that H. Lee Moffitt Cancer Center ("Moffitt") plans to present clinical results from a Phase 1 trial using Moffitt’s tumor infiltrating lymphocytes (TIL) in patients with non-small cell lung cancer (NSCLC) at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting I, to be held April 27-28, 2020 (Press release, Iovance Biotherapeutics, APR 13, 2020, View Source [SID1234556314]). The Phase 1 study is being conducted at Moffitt with support from Iovance Biotherapeutics, a Stand Up To Cancer Catalyst grant, and other partners.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Maria Fardis, Ph.D., MBA, President and Chief Executive Officer of Iovance, stated, "We are very pleased that Moffitt will present clinical data demonstrating the potential for tumor infiltrating lymphocytes, or TIL, in such an unmet medical need indication, non-small cell lung cancer. This data is the basis of our strategy to investigate Iovance TIL in two cohorts of non-small cell lung cancer patients in our IOV-COM-202 ‘basket’ study. We continue to be excited about the broader potential of Iovance TIL in additional tumor types."
Abstract Title: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): a phase I trial.
Authors: Ben Creelan, et al.
Session: VCTPL05 – Adoptive Cell Transfer Therapy
Date and Time: April 28, 2020, 12:45 PM – 12:55 PM
Abstract Number: 20-LB-10617-AACR
Location: AACR (Free AACR Whitepaper) Virtual Annual Meeting I at www.aacr.org
The AACR (Free AACR Whitepaper) Virtual Annual Meeting I will include more than 30 oral presentations in several clinical trial plenary sessions along with commentaries from expert discussants, as well as clinical trial poster sessions consisting of short videos providing the authors’ perspectives. This Virtual Meeting will be available free to everyone, although attendees will be asked to register to participate. For more information please visit the AACR (Free AACR Whitepaper) Virtual Annual Meeting I page at www.aacr.org.